Key numbers

Key numbers of Institut Pasteur

big_focus_11

Key numbers

Creation Date

1887

Workforce

2600 , of more than 60 different nationalities

Annual Budget

239,3 million euros 2008

Research units, groups

130

Technological Platforms

24

Students and trainees

1000

National Reference Centres

20

WHO Collaborating Centres

8

International Network

32 Instituts Pasteur

Start-up in biotechnology

14

Medical Centre (chiffres 2009)

85 449 vaccinations, 23 207 consultations, 14 272 analysis


Research

Vignette_34

130 biology research laboratories and units, belonging to 10 research departments, prioritising the fight against infectious diseases (microbiology):

  Cell Biology and Infection
  Developmental Biology
  Genomes and Genetics
  Immunology
  Infection and Epidemiology
  Microbiology
  Neuroscience
  Parasitology and Mycology
  Structural Biology and Chemistry
  Virology

The research also focuses on other diseases such as certain cancers, genetic diseases, neurodegenerative diseases, and allergy.

The Institut Pasteur research units also include:

  21 National Reference Centres
  7 WHO Collaborating Centres


Research applications
              485 priority patents in portfolio

Creation of biotech start-up companies :


Companies

Creation

Activities

Hybrigenics

1997

Identification, selection and validation of high quality therapeutic targets
News chemical entities in oncology

Diatos

1999

Intracellular/intranuclear drug delivery systems
Prodrug technologies / Tumor Targeting

Cellectis

2000

Meganuclease Recombination Systems

Pasteur Media Vita 2000 From consulting to training, edition and communication, Pasteur MediaVita develop health educational tools and solutions in prevention for general public, private companies and health professionals

Celogos

2001

Celogos is a biotechnology company focused on developing and producing innovative cell-based technologies in the field of cellular medicine.
The company’s expertise is in the restoration of tissue function, especially muscle regeneration.

Theraptosis

2001

Development of molecules to control apoptosis

Genticel (ex-BT Pharma)

2001

Genticel is a bio-pharmaceutical company, created in 2001 and spun out from the Institut Pasteur in 2002. The company strives to improve the well-being of people through the development of therapeutic vaccines for infection, dysplasia and cancer provoked by the Human Papillomavirus (HPV).

Biocortech

 2001

Identification and validation of new molecules modulating the expression and activity of key proteins involved in neuronal function.
Repair of phenotypic deficits

Anaconda Pharma

2003

Development of low molecular weight viral inhibitors
Therapeutic areas : condylomas (genital warts), ano-genital dysplasias, skin warts.

Texcell

 2003

To provide to Pharmaceutical Industry with tools assays and services in accordance with the international recommendation (EU, FDA-USA, Japanese MHW, WHO and ICH) to help the development of medicinal products

Génomic Vision

2004

DNA – based diagnostic tests 
Discovering new drug targets
Drug development

Ariana Pharma

 2005

Ariana™ Pharma delivers intelligent tools to dramatically improve decision-making in the fields of discovery, development and safety for the pharmaceutical industry. Its KEM® knowledge extraction and management system comprehensively mines data, identifying relations that other systems neglect, and helps scientists take decisions involving a wide range of criteria and objectives.

Cognium Systems

2005

Cognium Systems develops and sells next-generation software systems designed to dramatically improve organization and management of knowledge discovered in the process of biomedical research. Moreover, the software will be extended and applied to solve related problems in other fields, such as medical, legal, and manufacturing.

 TheraVectys 2007

TheraVectys SA is a biotechnological company founded in November 2006 and located in incubator section of the Pasteur Institute in Paris. TheraVectys is developing new generation of vaccines based on an innovative process, i.e. lentiviral «DNA Flap » vectors. These vaccines are able to target different pathogenic agents (viruses, bacteria, parasites) as well as different types of tumors. The company intends to develop prophylactic and therapeutic vaccines for several human and veterinary applications.



Teaching

Vignette_54

525 carefully selected students of 45 different nationalities.

 The 28 courses run by the Institut Pasteur Teaching center are postgraduate university training programmes comprising highly developed practical work. Certain courses lead to an inter-university diploma and several form part of the doctoral training in a number of Paris universities.


Public health

Vignette_65

The Institut Pasteur Medical Centre provides the following services to the public:

- Consultations: Infectious and tropical diseases Travel medicine Allergy
- Vaccinations and advice to travellers
- Rabies centre
- Medical biology analysis laboratory


International Network of Pasteur institutes

Vignette_69
32 institutes spread over five continents

The institutes belonging to the network, including the Institut Pasteur in Paris, are extremely involved in public health in the countries in which they are located, in agreement with the local health authorities: medical biology, vaccinations, microbiological monitoring etc. The majority is recognised as reference centres on a national level or within the framework of the WHO. Education is another major mission of the institutes in the network which provide training for numerous trainees from the countries concerned and from abroad. The research carried out, in the field and in the laboratory, concerns infectious diseases (influenza, AIDS, arbovirus diseases, malaria, plague, etc.) affecting the host country. Through this network, the development of numerous diseases throughout the world is meticulously monitored by the Pasteur community.